Vertex Pharmaceuticals’ kidney disease drug hits key milestone in phase 3 trial
New England Council member Vertex Pharmaceuticals announced that povetacicept, its kidney disease drug acquired through a $4.9 billion purchase of Seattle-based Alpine Immune Sciences in 2024, has met its main goal in an interim analysis of an ongoing Phase 3 trial in patients with immunoglobulin A nephropathy (IgAN) — a condition in which a protein builds up in the kidneys, impairing their ability to filter waste from the blood.
The results give the Boston-based company sufficient confidence to seek accelerated FDA approval, with Vertex planning to complete its submission by the end of March. The company is also using a priority review voucher to shorten the review timeline from 10 months to 6 months. If approved, povetacicept would be administered via a subcutaneous auto-injector that patients could use at home every four weeks. Vertex is already looking beyond IgAN, with an ongoing Phase 2/3 trial in primary membranous nephropathy and a Phase 2 trial in generalized myasthenia gravis expected to begin in the first half of 2026.
“Povetacicept demonstrates best-in-class potential and establishes renal medicine as Vertex’s fourth franchise alongside cystic fibrosis, hematology and acute pain,” said Vertex CEO Reshma Kewalramani.
The New England Council commends Vertex Pharmaceuticals for this significant clinical milestone and its continued leadership in developing innovative treatments that address serious unmet medical needs.
Read more on the Boston Business Journal